Charles Drake, MD
Medical Oncology · New York, NYNPI 1346297397
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 28.3% of the total. Reporting peaked in 2019 at $110,183 and has fallen 97.8% since, to $2,474 in 2021.
Across 141 payments — averaging $933.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$37K
- E.r. Squibb & Sons, L.L.C.$31K
- Ferring Pharmaceuticals Inc.$16K
- Janssen Global Services, LLC$9K
- Pfizer$8K
- Sanofi US Services Inc.$7K
- plus $23K from 14 others
Across 51 payments — averaging $34,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
- E.r. Squibb & Sons, L.L.C.$295K
- Regeneron$159K
- Genentech, Inc.$118K
- Ferring Pharmaceuticals Inc.$58K
- Merck$36K
- plus $9K from 2 others
What the payments were for
- Consulting fees$76,13458%
- Speaking & faculty fees$22,50017%
- Travel & lodging$29,02922%
- Food & beverage$3,9393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 24 | $37,234 |
| E.r. Squibb & Sons, L.L.C. | 42 | $31,303 |
| Ferring Pharmaceuticals Inc. | 10 | $16,497 |
| Janssen Global Services, LLC | 4 | $8,573 |
| Pfizer | 7 | $8,043 |
| Sanofi US Services Inc. | 5 | $7,314 |
| Bayer | 5 | $7,127 |
| EMD Serono, Inc. | 7 | $5,621 |
| Sanofi-aventis U.S. LLC | 3 | $2,474 |
| Janssen Scientific Affairs, LLC | 2 | $2,184 |
| F. Hoffmann-la Roche AG | 5 | $1,714 |
| Astrazeneca AB | 9 | $1,573 |
| GSK | 1 | $650 |
| Janssen Research & Development, LLC | 5 | $486 |
| Sanofi | 6 | $410 |
| Daiichi Sankyo Inc. | 1 | $136 |
| Astellas Pharma US Inc | 2 | $106 |
| Johnson & Johnson | 1 | $92 |
| Bristol Myers Squibb | 1 | $34 |
| Genentech, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$7,000
- NO PRODUCT DISCUSSED$4,818
- INLYTA$3,757
- Erleada$2,184
- BAVENCIO$1,890
- Non-Covered Product$1,601
- KEYTRUDA$602
How this compares
$131,602 in reported general payments places this provider in the 85th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.